Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Isomoto K, Haratani K, Tsujikawa T, Makutani Y, Kawakami H, Takeda M, Yonesaka K, Tanaka K, Iwasa T, Hayashi H, Ito A, Nishio K, Nakagawa K. Isomoto K, et al. Among authors: tsujikawa t. Lung Cancer. 2022 Dec;174:71-82. doi: 10.1016/j.lungcan.2022.10.012. Epub 2022 Oct 30. Lung Cancer. 2022. PMID: 36347190
Rapid multiplex immunohistochemistry for characterizing tumor-immune microenvironment.
Kimura A, Tsujikawa T, Morimoto H, Saburi S, Mitsuda J, Mukudai S, Nagao H, Shibata S, Ogi H, Miyagawa-Hayashino A, Konishi E, Itoh K, Hirano S. Kimura A, et al. Among authors: tsujikawa t. Heliyon. 2024 Jun 28;10(13):e33830. doi: 10.1016/j.heliyon.2024.e33830. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39050465 Free PMC article.
Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.
Tsujikawa T, Ohno K, Morita KI, Saburi S, Mitsuda J, Yoshimura K, Kimura A, Morimoto H, Ogi H, Shibata S, Akashi T, Kurata M, Imoto I, Shimizu Y, Kano S, Watanabe A, Yamazaki T, Asada Y, Hayashi R, Saito Y, Ozawa H, Tsukahara K, Oridate N, Sano D, Horii A, Ueki Y, Maruo T, Mukoyama N, Hanai N, Fukusumi T, Iwai H, Fujisawa T, Fujii T, Nibu KI, Iwae S, Ueda T, Chikuie N, Yasumatsu R, Matsuo M, Umeno H, Ono T, Masuda M, Toh S, Itoh K, Hirano S, Asakage T. Tsujikawa T, et al. Front Immunol. 2024 Jul 29;15:1390873. doi: 10.3389/fimmu.2024.1390873. eCollection 2024. Front Immunol. 2024. PMID: 39136017 Free PMC article.
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.
Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Reddy SM, et al. Among authors: tsujikawa t. Cancer Immunol Res. 2019 Jun;7(6):1025-1035. doi: 10.1158/2326-6066.CIR-18-0619. Epub 2019 May 1. Cancer Immunol Res. 2019. PMID: 31043414 Free PMC article.
Quantitative multiplex immunohistochemistry reveals inter-patient lymphovascular and immune heterogeneity in primary cutaneous melanoma.
Femel J, Hill C, Illa Bochaca I, Booth JL, Asnaashari TG, Steele MM, Moshiri AS, Do H, Zhong J, Osman I, Leachman SA, Tsujikawa T, White KP, Chang YH, Lund AW. Femel J, et al. Among authors: tsujikawa t. Front Immunol. 2024 Feb 1;15:1328602. doi: 10.3389/fimmu.2024.1328602. eCollection 2024. Front Immunol. 2024. PMID: 38361951 Free PMC article.
Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.
Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D, El Rassi E, Clayburgh DR, Kulesz-Martin MF, Lutz ER, Zheng L, Jaffee EM, Leyshock P, Margolin AA, Mori M, Gray JW, Flint PW, Coussens LM. Tsujikawa T, et al. Cell Rep. 2017 Apr 4;19(1):203-217. doi: 10.1016/j.celrep.2017.03.037. Cell Rep. 2017. PMID: 28380359 Free PMC article.
354 results